Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
European Surgery
Published in: European Surgery 3/2018

Open Access 01-06-2018 | main topic

Shaping the future of liver surgery

Implementation of experimental insights into liver regeneration

Authors: D. Pereyra, P. Starlinger, MD, PhD

Published in: European Surgery | Issue 3/2018

Login to get access

Summary

Background

While liver surgery has become a safe and feasible operation technique, the incidence of postoperative liver dysfunction still remains a central problem. Approximately 10% of patients undergoing liver resection were shown to develop liver dysfunction, which is associated with an increased risk of morbidity and mortality. Yet, to date there is no effective treatment option for postoperative liver dysfunction available. The development of postoperative liver dysfunction was linked to a disruption in the liver’s potential to regenerate. Thus, it is importance to elucidate the underlying mechanisms of liver regeneration and to find potential therapeutic targets for the treatment of patients with postoperative liver dysfunction.

Methods

A review of the literature was carried out.

Results

We report on potential future interventions for improvement of liver regeneration after surgical resection. Moreover, we evaluate the benefits and drawbacks of hepatic progenitor cell therapy and hematopoietic stem cell therapy. However, the most significant improvement seems to come from molecular targets. Indeed, von Willebrand factor and its pharmacologic manipulation are among the most promising therapeutic targets to date. Furthermore, using the example of platelet-based therapy, we stress the potentially adverse effects of treatments for postoperative liver dysfunction.

Conclusion

The present review reports on the newest advances in the field of regenerative science, but also underlines the need for more research in the field of postoperative liver regeneration, especially in regard to translational studies.
Literature
1.
Fan ST, Lo CM, Liu CL, Lam CM, Yuen WK, Yeung C, Wong J. Hepatectomy for hepatocellular carcinoma: toward zero hospital deaths. Ann Surg. 1999;229:322–30.CrossRefPubMedPubMedCentral
2.
Belghiti J, Hiramatsu K, Benoist S, Massault P, Sauvanet A, Farges O. Seven hundred forty-seven hepatectomies in the 1990s: an update to evaluate the actual risk of liver resection. J Am Coll Surg. 2000;191:38–46.CrossRefPubMed
3.
Jarnagin WR, Gonen M, Fong Y, DeMatteo RP, Ben-Porat L, Little S, Corvera C, et al. Improvement in perioperative outcome after hepatic resection: analysis of 1,803 consecutive cases over the past decade. Ann Surg. 2002;236:397–406. discussion 406–397.CrossRefPubMedPubMedCentral
4.
5.
Shoup M, Gonen M, D’Angelica M, Jarnagin WR, DeMatteo RP, Schwartz LH, Tuorto S, et al. Volumetric analysis predicts hepatic dysfunction in patients undergoing major liver resection. J Gastrointest Surg. 2003;7:325–30.CrossRefPubMed
6.
Shubert CR, Habermann EB, Truty MJ, Thomsen KM, Kendrick ML, Nagorney DM. Defining perioperative risk after hepatectomy based on diagnosis and extent of resection. J Gastrointest Surg. 2014;18:1917–28.CrossRefPubMed
7.
Booth CM, Nanji S, Wei X, Mackillop WJ. Management and outcome of colorectal cancer liver metastases in elderly patients: a population-based study. JAMA Oncol. 2015;1:1111–9.CrossRefPubMed
8.
Gilg S, Sparrelid E, Isaksson B, Lundell L, Nowak G, Stromberg C. Mortality-related risk factors and long-term survival after 4460 liver resections in Sweden – a population-based study. Langenbecks Arch Surg. 2017;402:105–13.CrossRefPubMed
9.
Shubert CR, Habermann EB, Bergquist JR, Thiels CA, Thomsen KM, Kremers WK, Kendrick ML, et al. A NSQIP review of major morbidity and mortality of synchronous liver resection for colorectal metastasis stratified by extent of liver resection and type of Colorectal resection. J Gastrointest Surg. 2015;19:1982–94.CrossRefPubMed
10.
11.
Rahbari NN, Garden OJ, Padbury R, Brooke-Smith M, Crawford M, Adam R, Koch M, et al. Posthepatectomy liver failure: a definition and grading by the International Study Group of Liver Surgery (ISGLS). Surgery. 2011;149:713–24.CrossRefPubMed
12.
Lesurtel M, Graf R, Aleil B, Walther DJ, Tian Y, Jochum W, Gachet C, et al. Platelet-derived serotonin mediates liver regeneration. Science. 2006;312:104–7.CrossRefPubMed
13.
Skrzypczyk C, Truant S, Duhamel A, Langlois C, Boleslawski E, Koriche D, Hebbar M, et al. Relevance of the ISGLS definition of posthepatectomy liver failure in early prediction of poor outcome after liver resection: study on 680 hepatectomies. Ann Surg. 2014;260:865–70. discussion 870.CrossRefPubMed
14.
15.
Spee B, Carpino G, Schotanus BA, Katoonizadeh A, Vander Borght S, Gaudio E, Roskams T. Characterisation of the liver progenitor cell niche in liver diseases: potential involvement of Wnt and Notch signalling. Gut. 2010;59:247–57.CrossRefPubMed
16.
Karaca G, Swiderska-Syn M, Xie G, Syn WK, Kruger L, Machado MV, Garman K, et al. TWEAK/Fn14 signaling is required for liver regeneration after partial hepatectomy in mice. PLoS ONE. 2014;9:e83987.CrossRefPubMedPubMedCentral
17.
Espanol-Suner R, Carpentier R, Van Hul N, Legry V, Achouri Y, Cordi S, Jacquemin P, et al. Liver progenitor cells yield functional hepatocytes in response to chronic liver injury in mice. Gastroenterology. 2012;143(e1567):1564–1575.e7.CrossRefPubMed
18.
Petersen BE, Grossbard B, Hatch H, Pi L, Deng J, Scott EW. Mouse A6-positive hepatic oval cells also express several hematopoietic stem cell markers. Hepatology. 2003;37:632–40.CrossRefPubMed
19.
Alison MR, Poulsom R, Jeffery R, Dhillon AP, Quaglia A, Jacob J, Novelli M, et al. Hepatocytes from non-hepatic adult stem cells. Nature. 2000;406:257.CrossRefPubMed
20.
Katoonizadeh A, Poustchi H, Malekzadeh R. Hepatic progenitor cells in liver regeneration: current advances and clinical perspectives. Liver Int. 2014;34:1464–72.CrossRefPubMed
21.
Vassilopoulos G, Wang PR, Russell DW. Transplanted bone marrow regenerates liver by cell fusion. Nature. 2003;422:901–4.CrossRefPubMed
22.
Parekkadan B, van Poll D, Megeed Z, Kobayashi N, Tilles AW, Berthiaume F, Yarmush ML. Immunomodulation of activated hepatic stellate cells by mesenchymal stem cells. Biochem Biophys Res Commun. 2007;363:247–52.CrossRefPubMedPubMedCentral
23.
Kuo TK, Hung SP, Chuang CH, Chen CT, Shih YR, Fang SC, Yang VW, et al. Stem cell therapy for liver disease: parameters governing the success of using bone marrow mesenchymal stem cells. Gastroenterology. 2008;134:2111–2121, 2121.e1-3.CrossRefPubMedPubMedCentral
24.
25.
Kanaji S, Fahs SA, Shi Q, Haberichter SL, Montgomery RR. Contribution of platelet vs. endothelial VWF to platelet adhesion and hemostasis. J Thromb Haemost. 2012;10:1646–52.CrossRefPubMedPubMedCentral
26.
La Mura V, Reverter JC, Flores-Arroyo A, Raffa S, Reverter E, Seijo S, Abraldes JG, et al. Von Willebrand factor levels predict clinical outcome in patients with cirrhosis and portal hypertension. Gut. 2011;60:1133–8.CrossRefPubMed
27.
Kirschbaum M, Jenne CN, Veldhuis ZJ, Sjollema KA, Lenting PJ, Giepmans BNG, Porte RJ, et al. Transient von Willebrand factor-mediated platelet influx stimulates liver regeneration after partial hepatectomy in mice. Liver Int. 2017;37:1731–7.CrossRefPubMed
28.
Starlinger P, Alidzanovic L, Schauer D, Brugger P, Sommerfeldt S, Kuehrer I, Schoppmann SF, et al. Platelet-stored angiogenesis factors: clinical monitoring is prone to artifacts. Dis Markers. 2011;31:55–65.CrossRefPubMedPubMedCentral
29.
30.
Starlinger P, Assinger A, Haegele S, Wanek D, Zikeli S, Schauer D, Birner P, et al. Evidence for serotonin as a relevant inducer of liver regeneration after liver resection in humans. Hepatology. 2014;60:257–66.CrossRefPubMed
31.
Alpini G, Invernizzi P, Gaudio E, Venter J, Kopriva S, Bernuzzi F, Onori P, et al. Serotonin metabolism is dysregulated in cholangiocarcinoma, which has implications for tumor growth. Cancer Res. 2008;68:9184–93.CrossRefPubMedPubMedCentral
32.
Asada M, Ebihara S, Yamanda S, Niu K, Okazaki T, Sora I, Arai H. Depletion of serotonin and selective inhibition of 2B receptor suppressed tumor angiogenesis by inhibiting endothelial nitric oxide synthase and extracellular signal-regulated kinase 1/2 phosphorylation. Neoplasia. 2009;11:408–17.CrossRefPubMedPubMedCentral
33.
Gurbuz N, Ashour AA, Alpay SN, Ozpolat B. Down-regulation of 5‑HT1B and 5‑HT1D receptors inhibits proliferation, clonogenicity and invasion of human pancreatic cancer cells. PLoS ONE. 2014;9:e105245.CrossRefPubMedPubMedCentral
34.
Pang Q, Liu C, Zhang JY, Qu K, Song SD, Liu SS, Xu XS. Serotonin in liver tumor: friend or foe? Hepatology. 2015;62:319.CrossRefPubMed
35.
Padickakudy R, Pereyra D, Offensperger F, Jonas P, Oehlberger L, Schwarz C, Haegele S, et al. Bivalent role of intra-platelet serotonin in liver regeneration and tumor recurrence in humans. J Hepatol. 2017;67:1243–52.CrossRefPubMed
36.
Aryal B, Shimizu T, Kadono J, Furoi A, Komokata T, Inoue M, Ikeda S, et al. A Switch in the Dynamics of Intra-Platelet VEGF-A from Cancer to the Later Phase of Liver Regeneration after Partial Hepatectomy in Humans. PLoS ONE. 2016;11:e150446.CrossRefPubMedPubMedCentral
Metadata
Title
Shaping the future of liver surgery
Implementation of experimental insights into liver regeneration
Authors
D. Pereyra
P. Starlinger, MD, PhD
Publication date
01-06-2018
Publisher
Springer Vienna
Published in
European Surgery / Issue 3/2018
Print ISSN: 1682-8631
Electronic ISSN: 1682-4016
DOI
https://doi.org/10.1007/s10353-018-0515-3

Other articles of this Issue 3/2018

European Surgery 3/2018 Go to the issue

main topic

Integrating interventional oncology in the treatment of liver tumors

main topic

Perioperative management of liver surgery—review on pathophysiology of liver disease and liver failure

editorial

Surgery and the Eye of Horus: the myth of mankind (Part I)

main topic

Optimal perioperative care in peri-hilar cholangiocarcinoma resection

main topic

Surgical techniques and strategies for the treatment of primary liver tumours: hepatocellular and cholangiocellular carcinoma

main topic

Patient selection and perioperative optimisation in surgery for colorectal liver metastases